Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

In a report released yesterday, Charlie CY Yang from Bank of America Securities maintained a Hold rating on Amgen (AMGN – Research Report), ...

Amgen's MariTide achieves up to 20% weight loss in mid-stage trial, but analysts were expecting up to 25% Amgen Inc.'s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its ...

Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...

Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.